Evidence map›Paper›PMID 35800180›Full record

ReviewWorld journal of gastroenterology2022

Updates in therapeutic drug monitoring in inflammatory bowel disease.

Nilesh Lodhia, Shanti Rao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nilesh LodhiaDepartment of Gastroenterology and Hepatology, Atrium Health, Charlotte, NC 28203, United States. nilesh.lodhia@atriumhealth.org.
Shanti RaoDepartment of Gastroenterology and Hepatology, Atrium Health, Charlotte, NC 28203, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM.

Indexed as

Biological ProductsColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesDrug MonitoringGastrointestinal AgentsHumansImmunologic FactorsBiological ProductsGastrointestinal AgentsImmunologic FactorsCrohn’s diseaseInflammatory bowel diseaseTherapeutic drug monitoringUlcerative colitis

Identifiers

PMID35800180
PMCPMC9185221

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.